People grow old at different rates, regardless of what the calendar says. And for those whose bodies age more quickly, the cumulative effects show up as early as midlife, when signs of dementia and physical frailty begin to emerge, according to a study led by Duke researchers.
Read More
People who have a gene variant associated with an increased risk of developing Alzheimer’s disease also tend to have changes in the fluid around their brain and spinal cord that are detectable years before symptoms arise, according to new research from Duke Health.
Read More
An advisory committee to the US Food and Drug Administration largely concluded in a meeting on Friday that there is not enough evidence to support the effectiveness of the experimental Alzheimer’s disease drug aducanumab — and thus clinical data do not support approving the treatment.
Read More
Biogen stock soared 36% today on news FDA apparently is set to recommend approval of its treatment for Alzheimer’s. Here’s what’s happening.
Read More
T3D Therapeutics, a life science startup seeking to develop a treatment for Alzheimer’s disease, has another $740,000 to use in pursuit of its research courtesy of the Alzheimer’s Association and its partner Bill Gates.
Read More
A startup in Raleigh backed by investor and Pink Ceiling CEO Cindy Eckert, is unveiling Thursday a different approach to dealing with Alzheimer’s that is powered by artificial intelligence, not drugs.
Read More
Biomedical engineers at Duke University have devised a new imaging device capable of measuring both the thickness and texture of the various layers of the retina at the back of the eye. The advance could be used to detect a biomarker of Alzheimer’s disease, potentially offering a widespread early warning system for the disease.
Read More
T3D Therapeutics, a 7-year-old company started with loan help from the North Carolina Biotechnology Center, said today it is launching a Phase 2 clinical trial with its unique product candidate, T3D-959, to treat mild to moderate forms of Alzheimer’s disease (AD).
Read More
T3D Therapeutics has raised $15 million in new financing to fund continued development of its proposed treatment of Alzheimer’s, one that the company says has the potential to slow, stop or reverse the course of the disease
Read More
